New obesity drugs yield unexpected results: Not just weight loss

Millions worldwide are using new GLP-1 receptor agonists and dual-action drugs to treat obesity and metabolic diseases. As these medications become more common, scientists are gaining a clearer understanding of their effects, which extend beyond initial expectations.

Researchers are observing a range of positive outcomes. Studies suggest these drugs may reduce inflammation and lower the risk of certain cardiovascular and musculoskeletal conditions. Emerging evidence also indicates potential benefits in reducing alcohol consumption and mitigating risks associated with substance use disorders, though further clinical trials are needed to confirm these findings.

However, questions persist regarding the impact on lean body mass and nutritional intake. Some research indicates that a portion of the weight lost may come from muscle mass, highlighting the need for studies on how physical activity and diet can help preserve muscle. Additionally, the appetite-suppressing nature of these drugs could increase the risk of vitamin and mineral deficiencies in some patients.

Future research will focus on understanding the mechanisms behind reduced inflammation, precisely measuring changes in lean body mass through randomized trials, and exploring ways to maintain muscle. Scientists also aim to conduct larger studies to determine the drugs' efficacy in managing alcohol-related disorders. Despite unanswered questions, current evidence suggests a favorable balance of benefits over risks for these medications.